Search
SAB Biotherapeutics Inc
SABSAdd to Watchlist
3.350USD
-0.040-1.18%
Close 09-24 16:00（ET）
256.14MMarket Cap
7.83P/E TTM
SAB Biotherapeutics Inc (SABS) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to SAB Biotherapeutics Inc in the past month.
Buy
5 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.636USD+243.26%
SABS Analyst Recommendation Trends
In the current month, SABS has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SABS average Analyst price target in the last month is 11.636.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
3
3
3
3
3
2
6
6
5
5
5
5
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
8
8
8
8
7
6
SABS Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, SABS EPS is projected to reach -0.273 in FY2026Q3, following reported EPS of -0.282 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.20
-0.23
-0.29
-0.27
-0.26
Actual
-0.06
-0.35
-0.28
--
--
Surprise
+70.17%
-54.29%
+2.55%
--
--
FAQs
What is SAB Biotherapeutics Inc's price target?
Analysts forecast that SAB Biotherapeutics Inc's price target is USD 11.64, with the highest forecast at USD 16.00 and the lowest forecast at USD 6.00.
How have SAB Biotherapeutics IncSABS's recent earnings per share performed?
The market expectation was USD -0.28, while SAB Biotherapeutics IncSABS's earnings per share (EPS) for the previous quarter was USD -0.35. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for SAB Biotherapeutics Inc?
Based on the ratings of SAB Biotherapeutics Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.